ProShares Ultra NASDAQ Biotechnology
BIB
7 hedge funds and large institutions have $2.52M invested in ProShares Ultra NASDAQ Biotechnology in 2013 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
38% more capital invested
Capital invested by funds: $1.82M → $2.52M (+$696K)
13% less funds holding
Funds holding: 8 → 7 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$646K |
| 2 |
PCM
Prelude Capital Management
New York
|
+$413K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$25.5K |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$23.2K |
| 5 |
AIG
American International Group
New York
|
+$11.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$805K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$45.1K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$23K |
| 4 |
CA
CapWealth Advisors
Franklin,
Tennessee
|
-$1K |
BIB Hedge Fund Activity: Q3 2013 in Review
7 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2013, worth a combined $2.52M — up 38% from $1.82M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BIB and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.
The largest buyer was LPL Financial, adding an estimated $646K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $805K sold.
- 7 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2013, down from 8 in Q2 2013.
- Funds reported $2.52M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2013, up 38% quarter-over-quarter.
- 2 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2013 and 3 closed out, a net change of -1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2013 was LPL Financial, an estimated $646K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2013 was Susquehanna International Group, an estimated $805K sold.
Based on aggregated 13F filings for Q3 2013.